Integrative post-genome-wide association analysis of CDKN2A and TP53 SNPs and risk of esophageal adenocarcinoma

Carcinogenesis

Volumn 35, Issue 12, 2014, Pages 2740-2747

  Buas, Matthew F ^a,b   Levine, David M ^a   Makar, Karen W ^b   Utsugi, Heidi ^b   Onstad, Lynn ^b   Li, Xiaohong ^b   Galipeau, Patricia C ^b   Shaheen, Nicholas J ^c   Hardie, Laura J ^d   Romero, Yvonne ^e   Bernstein, Leslie ^f   Gammon, Marilie D ^g   Casson, Alan G ^h   Bird, Nigel C ⁱ   Risch, Harvey A ^j   Ye, Weimin ^k   Liu, Geoffrey ^l   Corley, Douglas A ^m,n   Blount, Patricia L ^b   Fitzgerald, Rebecca C ^o   Whiteman, David C ^p   Wu, Anna H ^q   Reid, Brian J ^b   Vaughan, Thomas L ^a,b   more..

^a UNIVERSITY OF WASHINGTON   (United States)

^b USA   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e MAYO CLINIC   (United States)

^f CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^g University of North Carolina at Chapel Hill   (United States)

^h UNIVERSITY OF SASKATCHEWAN   (Canada)

ⁱ UNIVERSITY OF SHEFFIELD   (United Kingdom)

^j YALE UNIVERSITY   (United States)

^k KAROLINSKA INSTITUTE   (Sweden)

^l PRINCESS MARGARET HOSPITAL   (Canada)

^m DIVISION OF RESEARCH   (United States)

ⁿ KAISER PERMANENTE   (United States)

^o HUTCHISON MRC RESEARCH CENTRE   (United Kingdom)

^p QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^q UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; MICRORNA; MICRORNA 663B; PROTEIN P53; SMALL UNTRANSLATED RNA; UNCLASSIFIED DRUG; TP53 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; BINDING SITE; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; ESOPHAGEAL ADENOCARCINOMA; EVIDENCE BASED PRACTICE; FEMALE; GENE REPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; ADENOCARCINOMA; CANCER STAGING; CASE CONTROL STUDY; COMPARATIVE STUDY; ESOPHAGUS TUMOR; FOLLOW UP; GENETICS; PATHOLOGY; PROGNOSIS;

ADENOCARCINOMA; AGED; BARRETT ESOPHAGUS; CASE-CONTROL STUDIES; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84926412178     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu207     Document Type: Article

References (73)

1. Holmes, R.S. et al. (2007) Epidemiology and pathogenesis of esophageal cancer. Semin. Radiat. Oncol., 17, 2-9.
2. Lagergren, J. et al. (1999) Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N. Engl. J. Med., 340, 825-831.
3. Reid, B.J. et al. (2010) Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat. Rev. Cancer, 10, 87-101.
4. Moons, L.M. et al. (2007) COX-2 CA-haplotype is a risk factor for the development of esophageal adenocarcinoma. Am. J. Gastroenterol., 102, 2373-2379.
5. Kristinsson, J.O. et al. (2009) Cyclooxygenase-2 polymorphisms and the risk of esophageal adeno-or squamous cell carcinoma. World J. Gastroenterol., 15, 3493-3497.
6. Babar, M. et al. (2012) Genes of the interleukin-18 pathway are associated with susceptibility to Barrett's esophagus and esophageal adenocarcinoma. Am. J. Gastroenterol., 107, 1331-1341.
7. Menke, V. et al. (2012) NcoI TNF-ß gene polymorphism and TNF expression are associated with an increased risk of developing Barrett's esophagus and esophageal adenocarcinoma. Scand. J. Gastroenterol., 47, 378-386.
8. Casson, A.G. et al. (2006) Genetic polymorphisms of microsomal epoxide hydroxylase and glutathione S-transferases M1, T1 and P1, interactions with smoking, and risk for esophageal (Barrett) adenocarcinoma. Cancer Detect. Prev., 30, 423-431.
9. Bull, L.M. et al. (2009) Phase I and II enzyme polymorphisms as risk factors for Barrett's esophagus and esophageal adenocarcinoma: a systematic review and meta-analysis. Dis. Esophagus, 22, 571-587.
10. di Martino, E. et al. (2007) The NAD(P)H:quinone oxidoreductase I C609T polymorphism modifies the risk of Barrett esophagus and esophageal adenocarcinoma. Genet. Med., 9, 341-347.
11. Doecke, J. et al.; Australian Cancer Study. (2008) Polymorphisms in MGMT and DNA repair genes and the risk of esophageal adenocarcinoma. Int. J. Cancer, 123, 174-180.
12. Zhai, R. et al. (2008) Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma risk. Carcinogenesis, 29, 2330-2334.
13. Cheung, W.Y. et al. (2012) Single nucleotide polymorphisms in the matrix metalloproteinase gene family and the frequency and duration of gastroesophageal reflux disease influence the risk of esophageal adenocarcinoma. Int. J. Cancer, 131, 2478-2486.
14. Liu, C.Y. et al. (2010) A Large-scale genetic association study of esophageal adenocarcinoma risk. Carcinogenesis, 31, 1259-1263.
15. Su, Z. et al.; Esophageal Adenocarcinoma Genetics Consortium; Wellcome Trust Case Control Consortium 2. (2012) Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nat. Genet., 44, 1131-1136.
16. Levine, D.M. et al. (2013) A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett's esophagus. Nat. Genet., 45, 1487-1493.
17. Pierce, B.L. et al. (2011) Genome-wide "pleiotropy scan" identifies HNF1A region as a novel pancreatic cancer susceptibility locus. Cancer Res., 71, 4352-4358.
18. Pierce, B.L. et al. (2011) Association study of type 2 diabetes genetic susceptibility variants and risk of pancreatic cancer: an analysis of PanScan-I data. Cancer Causes Control, 22, 877-883.
19. Reid, B.J. (2010) Early events during neoplastic progression in Barrett's esophagus. Cancer Biomark., 9, 307-324.
20. Paulson, T.G. et al. (2009) Chromosomal instability and copy number alterations in Barrett's esophagus and esophageal adenocarcinoma. Clin. Cancer Res., 15, 3305-3314.
21. Li, X. et al. (2014) Temporal and spatial evolution of somatic chromosomal alterations: a case-cohort study of Barrett's esophagus. Cancer Prev. Res. (Phila)., 7, 114-127.
22. Casson, A.G. et al. (1991) p53 gene mutations in Barrett's epithelium and esophageal cancer. Cancer Res., 51, 4495-4499.
23. Blount, P.L. et al. (1994) 17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy. Cancer Res., 54, 2292-2295.
24. Galipeau, P.C. et al. (1996) 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Proc. Natl. Acad. Sci. USA, 93, 7081-7084.
25. Barrett, M.T. et al. (1996) Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. Oncogene, 13, 1867-1873.
26. Galipeau, P.C. et al. (1999) Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue. J. Natl. Cancer Inst., 91, 2087-2095.
27. Wong, D.J. et al. (2001) p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res., 61, 8284-8289.
28. Paulson, T.G. et al. (2008) p16 mutation spectrum in the premalignant condition Barrett's esophagus. PLoS One, 3, e3809.
29. Reid, B.J. et al. (2001) Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am. J. Gastroenterol., 96, 2839-2848.
30. Galipeau, P.C. et al. (2007) NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med., 4, e67.
31. Prevo, L.J. et al. (1999) p53-mutant clones and field effects in Barrett's esophagus. Cancer Res., 59, 4784-4787.
32. Barrett, M.T. et al. (1999) Evolution of neoplastic cell lineages in Barrett oesophagus. Nat. Genet., 22, 106-109.
33. Maley, C.C. et al. (2004) Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus. Cancer Res., 64, 3414-3427.
34. Maley, C.C. et al. (2004) The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma. Cancer Res., 64, 7629-7633.
35. Maley, C.C. et al. (2006) Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat. Genet., 38, 468-473.
36. Kostadinov, R.L. et al. (2013) NSAIDs modulate clonal evolution in Barrett's esophagus. PLoS Genet., 9, e1003553.
37. Dulak, A.M. et al. (2013) Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat. Genet., 45, 478-486.
38. Amos, C.I. et al.; GenoMEL Investigators; Q-Mega Investigators; AMFS Investigators. (2011) Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. Hum. Mol. Genet., 20, 5012-5023.
39. Laurie, C.C. et al.; GENEVA Investigators. (2010) Quality control and quality assurance in genotypic data for genome-wide association studies. Genet. Epidemiol., 34, 591-602.
40. Hardikar, S. et al. (2013) The role of tobacco, alcohol, and obesity in neoplastic progression to esophageal adenocarcinoma: a prospective study of Barrett's esophagus. PLoS One, 8, e52192.
41. Gray, K.A. et al. (2013) Genenames.org: the HGNC resources in 2013. Nucleic Acids Res., 41(Database issue), D545-D552.
42. Newton, H.J. et al. (2003) Multiple-test procedures and smile plots. Stata J., 3, 109-132.
43. Lewis, B.P. et al. (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell, 120, 15-20.
44. John, B. et al. (2004) Human MicroRNA targets. PLoS Biol., 2, e363.
45. Hiard, S. et al. (2010) Patrocles: a database of polymorphic miRNA-mediated gene regulation in vertebrates. Nucleic Acids Res., 38(Database issue), D640-D651.
46. Ryan, B.M. et al. (2010) Genetic variation in microRNA networks: the implications for cancer research. Nat. Rev. Cancer, 10, 389-402.
47. Lengauer, C. et al. (1998) Genetic instabilities in human cancers. Nature, 396, 643-649.
48. Carter, S.L. et al. (2012) Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol., 30, 413-421.
49. Weaver, J.M.J. et al. (2014) The "-omics" revolution and oesophageal adenocarcinoma. Nat. Rev. Gastroenterol. Hepatol., 11, 19-27.
50. Hansson, J. (2010) Familial cutaneous melanoma. Adv. Exp. Med. Biol., 685, 134-145.
51. Kumar, R. et al. (2001) A single nucleotide polymorphism in the 3'untranslated region of the CDKN2A gene is common in sporadic primary melanomas but mutations in the CDKN2B, CDKN2C, CDK4 and p53 genes are rare. Int. J. Cancer, 95, 388-393.
52. Maccioni, L. et al. (2013) Variants at the 9p21 locus and melanoma risk. BMC Cancer, 13, 325.
53. Debniak, T. et al. (2005) CDKN2A common variants and their association with melanoma risk: a population-based study. Cancer Res., 65, 835-839.
54. Pjanova, D. et al. (2007) CDKN2A and CDK4 variants in Latvian melanoma patients: analysis of a clinic-based population. Melanoma Res., 17, 185-191.
55. Ibarrola-Villava, M. et al. (2010) Genetic analysis of three important genes in pigmentation and melanoma susceptibility: CDKN2A, MC1R and HERC2/OCA2. Exp. Dermatol., 19, 836-844.
56. Aitken, J. et al. (1999) CDKN2A variants in a population-based sample of Queensland families with melanoma. J. Natl. Cancer Inst., 91, 446-452.
57. Straume, O. et al. (2002) Significant impact of promoter hypermethylation and the 540 C>T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase. Am. J. Pathol., 161, 229-237.
58. Sauroja, I. et al. (2000) Analysis of G(1)/S checkpoint regulators in metastatic melanoma. Genes Chromosomes Cancer, 28, 404-414.
59. Zheng, Y. et al. (2002) Haplotypes of two variants in p16 (CDKN2/MTS-1/INK4a) exon 3 and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Epidemiol. Biomarkers Prev., 11, 640-645.
60. Stone, S. et al. (1995) Complex structure and regulation of the P16 (MTS1) locus. Cancer Res., 55, 2988-2994.
61. Hull, J. et al. (2007) Identification of common genetic variation that modulates alternative splicing. PLoS Genet., 3, e99.
62. Alberobello, A.T. et al. (2011) An intronic SNP in the thyroid hormone receptor β gene is associated with pituitary cell-specific over-expression of a mutant thyroid hormone receptor ß2 (R338W) in the index case of pituitary-selective resistance to thyroid hormone. J. Transl. Med., 9, 144.
63. McLaren, W. et al. (2010) Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. Bioinformatics, 26, 2069-2070.
64. Mathelier, A. et al. (2014) JASPAR 2014: an extensively expanded and updated open-access database of transcription factor binding profiles. Nucleic Acids Res., 42(Database issue), D142-D147.
65. Ek, W.E. et al.; Mayo Clinic Esophageal Adenocarcinoma and Barrett's Esophagus Registry Consortium; BEACON study investigators. (2013) Germline genetic contributions to risk for esophageal adenocarcinoma, Barrett's esophagus, and gastroesophageal reflux. J. Natl. Cancer Inst., 105, 1711-1718.
66. Cunnington, M.S. et al. (2010) Chromosome 9p21 SNPs associated with multiple disease phenotypes correlate with ANRIL expression. PLoS Genet., 6, e1000899.
67. Yi, C. et al. (2012) MiR-663, a microRNA targeting p21(WAF1/CIP1), promotes the proliferation and tumorigenesis of nasopharyngeal carcinoma. Oncogene, 31, 4421-4433.
68. Liu, Z.Y. et al. (2011) MicroRNA-663 targets TGFB1 and regulates lung cancer proliferation. Asian Pac. J. Cancer Prev., 12, 2819-2823.
69. Yang, H. et al. (2009) MicroRNA expression signatures in Barrett's esophagus and esophageal adenocarcinoma. Clin. Cancer Res., 15, 5744-5752.
70. Pan, J. et al. (2010) Tumor-suppressive mir-663 gene induces mitotic catastrophe growth arrest in human gastric cancer cells. Oncol. Rep., 24, 105-112.
71. McDermott, K.M. et al. (2006) p16(INK4a) prevents centrosome dysfunction and genomic instability in primary cells. PLoS Biol., 4, e51.
72. Li, Y. et al. (2013) Polymorphisms in the p53 pathway genes and micronucleus occurrence in Chinese vinyl chloride-exposed workers. Int. J. Occup. Med. Environ. Health, 26, 825-836.
73. Ryan, A.M. et al. (2011) Obesity, metabolic syndrome and esophageal adenocarcinoma: epidemiology, etiology and new targets. Cancer Epidemiol., 35, 309-319.